These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 14695629

  • 1. Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia.
    Saxena A, Viswanathan S, Moshynska O, Tandon P, Sankaran K, Sheridan DP.
    Am J Hematol; 2004 Jan; 75(1):22-33. PubMed ID: 14695629
    [Abstract] [Full Text] [Related]

  • 2. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.
    Bannerji R, Kitada S, Flinn IW, Pearson M, Young D, Reed JC, Byrd JC.
    J Clin Oncol; 2003 Apr 15; 21(8):1466-71. PubMed ID: 12697868
    [Abstract] [Full Text] [Related]

  • 3. Abnormal intracellular level of Bax in CD3+ cells from untreated B-cell chronic lymphocytic leukemia patients.
    Scamardella F, Maconi M, Albertazzi L, Gamberi B, Gugliotta L, Brini M.
    Lab Hematol; 2006 Apr 15; 12(4):187-92. PubMed ID: 17118768
    [Abstract] [Full Text] [Related]

  • 4. A randomized trial comparing chlorambucil plus prednisone vs cyclophosphamide, melphalan, and prednisone in the treatment of chronic lymphocytic leukemia stages B and C.
    Montserrat E, Alcalá A, Alonso C, Besalduch J, Moraleda JM, García-Conde J, Gutierrez M, Gomis F, Garijo J, Guzmán MC.
    Nouv Rev Fr Hematol (1978); 1988 Apr 15; 30(5-6):429-32. PubMed ID: 3065738
    [Abstract] [Full Text] [Related]

  • 5. Determination of the in vivo effects of cladribine alone and its combination with cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and Bcl-2 protein expression in B-CLL cells.
    Kobylinska A, Blonski JZ, Hanausek M, Walaszek Z, Robak T, Kilianska ZM.
    Oncol Rep; 2004 Mar 15; 11(3):699-705. PubMed ID: 14767525
    [Abstract] [Full Text] [Related]

  • 6. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance.
    Thomas A, El Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M, Newcomb EW.
    Oncogene; 1996 Mar 07; 12(5):1055-62. PubMed ID: 8649796
    [Abstract] [Full Text] [Related]

  • 7. Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report.
    Ahmad I, Al-Katib AM, Beck FW, Mohammad RM.
    Clin Cancer Res; 2000 Apr 07; 6(4):1328-32. PubMed ID: 10778958
    [Abstract] [Full Text] [Related]

  • 8. Increased bcl-2/bax ratio in B-cell chronic lymphocytic leukemia is associated with a progressive pattern of disease.
    Molica S, Dattilo A, Giulino C, Levato D, Levato L.
    Haematologica; 1998 Dec 07; 83(12):1122-4. PubMed ID: 9949631
    [Abstract] [Full Text] [Related]

  • 9. Bcl-2 family of proteins in indolent B-cell non-Hodgkin's lymphoma: study of 116 cases.
    Agarwal B, Naresh KN.
    Am J Hematol; 2002 Aug 07; 70(4):278-82. PubMed ID: 12210808
    [Abstract] [Full Text] [Related]

  • 10. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR.
    J Clin Oncol; 2007 Mar 20; 25(9):1114-20. PubMed ID: 17296974
    [Abstract] [Full Text] [Related]

  • 11. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
    Bosanquet AG, Sturm I, Wieder T, Essmann F, Bosanquet MI, Head DJ, Dörken B, Daniel PT.
    Leukemia; 2002 Jun 20; 16(6):1035-44. PubMed ID: 12040435
    [Abstract] [Full Text] [Related]

  • 12. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses.
    Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, Wang HG, Zhang X, Bullrich F, Croce CM, Rai K, Hines J, Reed JC.
    Blood; 1998 May 01; 91(9):3379-89. PubMed ID: 9558396
    [Abstract] [Full Text] [Related]

  • 13. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX.
    McConkey DJ, Chandra J, Wright S, Plunkett W, McDonnell TJ, Reed JC, Keating M.
    J Immunol; 1996 Apr 01; 156(7):2624-30. PubMed ID: 8786328
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Expression of apoptosis regulators in cutaneous T-cell lymphoma (CTCL) cells.
    Zhang CL, Kamarashev J, Qin JZ, Burg G, Dummer R, Döbbeling U.
    J Pathol; 2003 Jun 01; 200(2):249-54. PubMed ID: 12754746
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Bcl-2 family gene modulation during spontaneous apoptosis of B-chronic lymphocytic leukemia cells.
    Sanz L, Garcia-Marco JA, Casanova B, de La Fuente MT, García-Gila M, Garcia-Pardo A, Silva A.
    Biochem Biophys Res Commun; 2004 Mar 12; 315(3):562-7. PubMed ID: 14975737
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
    Bosch F, Ferrer A, Villamor N, González M, Briones J, González-Barca E, Abella E, Gardella S, Escoda L, Pérez-Ceballos E, Asensi A, Sayas MJ, Font L, Altés A, Muntañola A, Bertazzoni P, Rozman M, Aymerich M, Giné E, Montserrat E.
    Clin Cancer Res; 2008 Jan 01; 14(1):155-61. PubMed ID: 18172266
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.